Monica Marcus

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2022;62:22-35
Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D₁ receptor dependent mechanism
Titulaer J; Radhe O; Danielsson K; Dutheil S; Marcus MM; Jardemark K; Svensson TH; Snyder GL; Ericson M; Davis RE; Konradsson-Geuken A
Article: SCIENCE ADVANCES. 2021;7(16):eabe6397
Rational antibody design for undruggable targets using kinetically controlled biomolecular probes
Trkulja CL; Jungholm O; Davidson M; Jardemark K; Marcus MM; Hagglund J; Karlsson A; Karlsson R; Bruton J; Ivarsson N; Srinivasa SP; Cavallin A; Svensson P; Jeffries GDM; Christakopoulou M-N; Reymer A; Ashok A; Willman G; Papadia D; Johnsson E; Orwar O
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2019;29(11):1282-1287
Enhancement of the antipsychotic effect of risperidone by sodium nitroprusside in rats
Titulaer J; Malmerfelt A; Marcus MM; Svensson TH
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2018;28(5):620-629
Functional mechanism of ASP5736, a selective serotonin 5-HT5A receptor antagonist with potential utility for the treatment of cognitive dysfunction in schizophrenia
Yamazaki M; Yamamoto N; Yarimizu J; Okabe M; Moriyama A; Furutani M; Marcus MM; Svensson TH; Harada K
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2017;27(4):411-417
The novel antipsychotic drug brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism
Bjorkholm C; Marcus MM; Konradsson-Geuken A; Jardemark K; Svensson TH
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2016;26(9):1401-1411
Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study
Marcus MM; Bjorkholm C; Malmerfelt A; Moller A; Pahlsson N; Konradsson-Geuken A; Feltmann K; Jardemark K; Schilstrom B; Svensson TH
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2014;18(3):pyu068
Adjunctive Treatment with Asenapine Augments the Escitalopram-Induced Effects on Monoaminergic Outflow and Glutamatergic Neurotransmission in the Medial Prefrontal Cortex of the Rat
Bjorkholm C; Franberg O; Malmerfelt A; Marcus MM; Konradsson-Geuken A; Schilstrom B; Jardemark K; Svensson TH
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2013;23(7):709-720
Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine
Bjorkholm C; Jardemark K; Marcus MM; Malmerfelt A; Nyberg S; Schilstrom B; Svensson TH
Article: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY AND BIOLOGICAL PSYCHIATRY. 2012;39(1):143-148
Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat
Johansson D; Falk A; Marcus MM; Svensson TH
Article: SYNAPSE. 2012;66(7):650-660
Involvement of 5-HT2A receptor and a2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow
Franberg O; Marcus MM; Svensson TH
Article: PSYCHOPHARMACOLOGY. 2012;221(1):115-131
Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission
Jardemark K; Marcus MM; Malmerfelt A; Shahid M; Svensson TH
Article: SYNAPSE. 2012;66(4):277-290
Augmentation by escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: Behavioral, biochemical, and electrophysiological evidence
Marcus MM; Jardemark K; Malmerfelt A; Gertow J; Konradsson-Geuken A; Svensson TH
Article: SYNAPSE. 2011;65(5):357-367
Effects of S-Citalopram, Citalopram, and R-Citalopram on the Firing Patterns of Dopamine Neurons in the Ventral Tegmental Area, N-methyl-D-aspartate Receptor-Mediated Transmission in the Medial Prefrontal Cortex and Cognitive Function in the Rat
Schilstrom B; Konradsson-Geuken A; Ivanov V; Gertow J; Feltmann K; Marcus MM; Jardemark K; Svensson TH
Article: SYNAPSE. 2010;64(11):870-874
Effects of Asenapine on Prefrontal N-methyl-D-Aspartate Receptor-Mediated Transmission: Involvement of Dopamine D1 Receptors
Jardemark K; Marcus MM; Shahid M; Svensson TH
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2010;13(7):891-903
Adjunctive α₂-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission
Marcus MM; Wiker C; Franberg O; Konradsson-Geuken A; Langlois X; Jardemark K; Svensson TH
Article: NEUROPSYCHOPHARMACOLOGY. 2010;35(9):1952-1961
Reboxetine Enhances the Olanzapine-Induced Antipsychotic-Like Effect, Cortical Dopamine Outflow and NMDA Receptor-Mediated Transmission
Marcus MM; Jardemark K; Malmerfelt A; Bjorkholm C; Svensson TH
Article: VACCINE. 2010;28(10):2161-2168
Nicotine hapten structure, antibody selectivity and effect relationships: Results from a nicotine vaccine screening procedure
de Villiers SHL; Lindblom N; Kalayanov G; Gordon S; Baraznenok I; Malmerfelt A; Marcus MM; Johansson AM; Svensson TH
Article: SYNAPSE. 2009;63(10):913-920
Differential Effects of Topiramate on Prefrontal Glutamatergic Transmission When Combined With Raclopride or Clozapine
Jardemark KE; Konradsson A; Schilstrom B; Marcus MM; Svensson TH
Article: PSYCHOPHARMACOLOGY. 2009;204(2):251-264
Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms
Franberg O; Marcus MM; Ivanov V; Schilstrom B; Shahid M; Svensson TH
Article: PSYCHOPHARMACOLOGY. 2008;196(3):417-429
Asenapine, a novel psychopharmacologic agent:: preclinical evidence for clinical effects in schizophrenia
Franberg O; Wiker C; Marcus MM; Konradsson A; Jardemark K; Schilstrom B; Shahid M; Wong EHF; Svensson TH
Article: EUROPEAN JOURNAL OF PHARMACOLOGY. 2007;573(1-3):148-160
Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dlhydro-1H-indol-3-yl)ethyl]-3, 6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: Characterisation of its in vitro profile and pre-clinical antipsychotic potential
Hertel P; Didriksen M; Pouzet B; BrennUrn LT; Soby KK; Larsen AK; Christoffersen CT; Ramirez T; Marcus MM; Svensson TH; Di Matteo V; Esposito E; Bang-Andersen B; Arnt J
Article: SYNAPSE. 2006;60(2):102-108
Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex
Konradsson A; Marcus MM; Hertel P; Svensson TH; Jardemark KE
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2005;8(3):315-327
Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat.
Marcus MM; Jardemark KE; Wadenberg M-L; Langlois X; Hertel P; Svensson TH
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2005;8(2):157-162
The combination of nicotine with the D₂ antagonist raclopride or the weak D₄ antagonist L-745,870 generates a clozapine-like facilitation of NMDA receptor-mediated neurotransmission in pyramidal cells of the rat medial prefrontal cortex
Jardemark K; Marcus MM; Konradsson Å; Svensson TH
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2002;12(5):379-386
Biochemical effects in brain of low doses of haloperidol are qualitatively similar to those of high doses
Marcus MM; Malmerfelt A; Nyberg S; Svensson TH
Article: NEUROPHARMACOLOGY. 2001;40(4):482-490
Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens.
Marcus MM; Mathé JM; Nomikos GG; Svensson TH
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2000;10(5):355-363
Effects of antipsychotic drugs on cholecystokinin and preprotachykinin (substance P) mRNA expression in the rat hippocampal formation
Zachrisson O; Nomikos GG; Marcus MM; Svensson TH; Lindefors N
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2000;10(4):245-253
Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism.
Marcus MM; Nomikos GG; Svensson TH
Article: ADVANCES IN PHARMACOLOGY. 1998;42:814-818
Interactions between catecholamines and serotonin: relevance to the pharmacology of schizophrenia.
Svensson TH; Mathé JM; Nomikos GG; Schilström B; Marcus M; Fagerquist M
Article: BRAIN RESEARCH. 1997;45(2):275-282
Effect of chronic antipsychotic drug treatment on preprosomatostatin and preprotachykinin A mRNA levels in the medial prefrontal cortex, the nucleus accumbens and the caudate putamen of the rat
Marcus MM; Nomikos GG; Malmerfelt A; Zachrisson O; Lindefors N; Svensson TH
Article: JOURNAL OF NEURAL TRANSMISSION. 1997;104(1):1-10
Differential effects of acute and chronic nicotine on dopamine output in the core and shell of the rat nucleus accumbens
Nisell M; Marcus M; Nomikos GG; Svensson TH
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1996;6(1):29-38
Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens.
Marcus MM; Nomikos GG; Svensson TH
Article: NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY. 1995;352(4):374-385
RITANSERIN POTENTIATES THE STIMULATORY EFFECTS OF RACLOPRIDE ON NEURONAL-ACTIVITY AND DOPAMINE RELEASE SELECTIVELY IN THE MESOLIMBIC DOPAMINERGIC SYSTEM
ANDERSSON JL; NOMIKOS GG; MARCUS M; HERTEL P; MATHE JM; SVENSSON TH
Visa fler

Alla övriga publikationer

Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2009;19:S562-S563
Enhanced cortical dopaminergic and glutamatergic transmission and antipsychotic-like effect of risperidone by idazoxan
Marcus MM; Wiker C; Franberg O; Konradsson-Geuken A; Langlois X; Jardemark K; Svensson TH
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2009;19:S561
Reboxetine enhances cortical dopaminergic and glutamatergic transmission and the anti psychotic-like effect of olanzapine
Svensson TH; Jardemark K; Malmerfelt A; Bjorkholm C; Marcus MM
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S477
Asenapine:: preclinical evidence for clinical effects in schizophrenia and cognitive dysfunction
Svensson TH; Frånberg O; Konradsson A; Jardemark K; Schilstroem B; Wiker C; Ivanov V; Shahid M; Wong EHF; Marcus MM
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S20-S21
Asenapine: preclinical evidence for clinical effects in Schizophrenia
Franberg O; Marcus MM; Konradsson A; Jardemark K; Schilstrom B; Wiker C; Shahid M; Wong EHF; Svensson TH
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S33-S34
Adjuvant treatment with the anticonvulsant drug topiramate in schizophrenia
Konradsson A; Marcus MM; Sitzia R; Svensson TH; Jardemark KE
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2006;16:s30-s31
Inhibition of glycine uptake augments risperidone's effect on prefrontal glutamatergic transmission
Konradsson A; Marcus MM; Hertel P; Svensson TH; Jardemark KE
Thesis / dissertation: 2005
Mechanism of action of antipsychotic drugs : focus on the nucleus accumbens and the prefronta cortex : an experimental study
Marcus, Monica M
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2003;13:s301
Addition of nicotine to the D₂ antagonist raclopride or the weak D₄ antagonist L-745,870 augments NMDA-induced currents in pyramidal cells from the rat medial prefrontal cortex
Marcus MM; Jardemark KE; Konradsson Å; Svensson TH
Meeting abstract: SCHIZOPHRENIA RESEARCH. 1998;29(1-2):170
Effects of atypical antipsychotic drugs on dopamine output in the shell and the core of the nucleus accumbens:: Role of 5-HT_2A and α₁-adrenoceptor antagonism
Marcus MM; Nomikos GG; Svensson TH
Published conference paper: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 1995;15(1):11S-18S
MODE OF ACTION OF ATYPICAL NEUROLEPTICS IN RELATION TO THE PHENCYCLIDINE MODEL OF SCHIZOPHRENIA - ROLE OF 5-HT2 RECEPTOR AND ALPHA(1)-ADRENOCEPTOR ANTAGONISM
SVENSSON TH; MATHE JM; ANDERSSON JL; NOMIKOS GG; HILDEBRAND BE; MARCUS M

Anställningar

Anknuten till Forskning, Fysiologi och farmakologi, Karolinska Institutet, 2023-2025

Examina och utbildning

MEDICINE DOKTORSEXAMEN, Institutionen för fysiologi och farmakologi, Karolinska Institutet, 2005
Medicine Magisterexamen, Karolinska Institutet, 2002
LICENTIATEXAMEN, Institutionen för fysiologi och farmakologi, Karolinska Institutet, 2002

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI